1. Scrip
  2. >>Business

As AbbVie’s Challenge Falters, Vertex Looks To Build On CF Dominance

Blockbuster Potential In Late-Stage Pipeline

 
• By Andrew McConaghie

Vertex is likely to have the cystic fibrosis market to itself for years to come, but investors are banking on it repeating that success in several new first-in-class therapy areas.

Vertex Mobile
Vertex's CF sales are set to reach $8.5bn this year, but investors are already looking ahead to opportunities in new therapy areas. • Source: Shutterstock

Vertex has been buoyed by sustained double-digit growth for its blockbuster cystic fibrosis therapies in Q1 and is looking to pass that momentum onto a next generation of treatments beyond its core franchise.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Veraxa Takes SPAC Route To Develop Bispecific ADCs and T-Cell Engagers

 
• By Andrew McConaghie

The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.

Pipeline Watch: Eight Approvals And Three Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

In Brief: Synthetic Design Lab Debuts With $20m To Advance Cutting-Edge ADCs

 
• By Sushmita Panda

As ADCs continue to be a growth area globally, a new US-based venture with novel platform technology has emerged from stealth mode with $20m in funding.